Coave Therapeutics unveils lead gene therapy program for retinal vascular diseases, powered by first-in-class vector for ...

SHELTON, CONNECTICUT / ACCESS Newswire / November 10, 2025 / NanoViricides, Inc. (NYSE American:NNVC) (the “Company”) today reported that it has received approval to Start Phase II Clinical Trial of ...

NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), today announced that it has entered into a securities purchase ...

SHELTON, CONNECTICUT / ACCESS Newswire / November 12, 2025 / NanoViricides, Inc. (NYSE American:NNVC) (the “Company”), today ...

A new study pinpoints the true resolution limit of human sight, showing that our eyes already max out on detail long before the latest 8K screens reach their full potential. As mobile displays ...

NV-387 Could be the Answer to the MPox Clade I Rising in the USA, Says Dr. Diwan SHELTON, CONNECTICUT / ACCESS Newswire / ...

Researchers in Sweden have developed a display technology with the smallest pixels ever made, capable of producing the highest resolution the human eye can perceive. The breakthrough could redefine ...

– Despite treatment with standard-of-care anti-seizure medicines, children with Dravet syndrome experienced high seizure burden and plateaued in neurodevelopment, resulting in a widening gap relative ...

Announces Date And Location Of 2025 Annual Shareholders Meeting. NanoViricides, Inc. (NYSE American: NNVC), a clinical-stage company developing broad-spectrum antiviral drugs designed to prevent viral ...

Despite treatment with standard-of-care anti-seizure medicines, children with Dravet syndrome experienced high seizure burden and plateaued in ...